Marker Therapeutics, Inc. (MRKR): who owns it and who trades it
As of Nov 12, 2026, no open-market insider purchases or sales of MRKR were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 12, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No MRKR insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
MRKR short interest
Low short interest. 1.1% of MRKR shares are sold short: about 1 share in 95. Over the last 12 reports the number of shares short went down 28%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 176,136 MRKR shares were sold short, 1.1% of the shares outstanding, up 61.4% from the report before. At the average daily volume of 255,474 shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 176,136 | 1.06% | +61% | 255,474 | 1.0 |
| Oct 15, 2026 | 109,110 | 0.65% | -35% | 97,400 | 1.1 |
| Sep 30, 2026 | 168,895 | 1.01% | -25% | 66,665 | 2.5 |
| Sep 15, 2026 | 226,620 | 1.36% | +63% | 67,897 | 3.3 |
| Aug 31, 2026 | 139,192 | 0.83% | -30% | 98,128 | 1.4 |
| Aug 14, 2026 | 200,212 | 1.20% | +30% | 52,084 | 3.8 |
| Jul 31, 2026 | 154,349 | 0.93% | -4% | 42,454 | 3.6 |
| Jul 15, 2026 | 160,940 | 0.97% | +38% | 79,349 | 2.0 |
| Jun 30, 2026 | 116,653 | 0.70% | -46% | 52,848 | 2.2 |
| Jun 15, 2026 | 217,647 | 1.31% | +6% | 62,676 | 3.5 |
| May 29, 2026 | 204,416 | 1.23% | -17% | 66,655 | 3.1 |
| May 15, 2026 | 244,966 | 1.47% | +63% | 64,788 | 3.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Marker Therapeutics company events
Marker Therapeutics filed 4 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Oct 19, 2026.
- Oct 19, 2026AnnouncementOther Information On October19, 2026, Marker Therapeutics, Inc. issued a press release announcing that it was awarded a $2.6 Million Grant by the Food & Drug Administration under the FDA’s Orphan Products development program to advance the Company’s lead investigational MAR-T cell therapy, MT-601… Filing
- May 4, 2026VoteReported shareholder vote results. Filing
- Mar 19, 2026ResultsReleased financial results. Filing
- Feb 9, 2026VoteSet dates for shareholder nominations. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Marker Therapeutics financials
Famous investors that hold MRKR
1 of the 50 well-known investors we track reported holding MRKR in their latest 13F filing. The largest position is Jim Simons's, worth $286K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 267,350 | $286K | 0.0% | +7% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Marker Therapeutics, Inc. (MRKR) stock
Are MRKR insiders buying or selling?
No MRKR insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in MRKR?
As of Oct 30, 2026, 176,136 MRKR shares were sold short, 1.1% of the shares outstanding, up 61.4% from the report before. At the average daily volume of 255,474 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold MRKR?
1 of the 50 well-known investors we track reported MRKR in their latest 13F filing, including Jim Simons. The largest position is worth $286K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.